Journal of Bioenergetics and Biomembranes

, Volume 44, Issue 1, pp 163–170 | Cite as

A translational study “case report” on the small molecule “energy blocker” 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside

  • Y. H. Ko
  • H. A. Verhoeven
  • M. J. Lee
  • D. J. Corbin
  • T. J. Vogl
  • P. L. Pedersen
Open Access
Article

Abstract

The small alkylating molecule, 3-bromopyruvate (3BP), is a potent and specific anticancer agent. 3BP is different in its action from most currently available chemo-drugs. Thus, 3BP targets cancer cells’ energy metabolism, both its high glycolysis (“Warburg Effect”) and mitochondrial oxidative phosphorylation. This inhibits/ blocks total energy production leading to a depletion of energy reserves. Moreover, 3BP as an “Energy Blocker”, is very rapid in killing such cells. This is in sharp contrast to most commonly used anticancer agents that usually take longer to show a noticeable effect. In addition, 3BP at its effective concentrations that kill cancer cells has little or no effect on normal cells. Therefore, 3BP can be considered a member, perhaps one of the first, of a new class of anticancer agents. Following 3BP’s discovery as a novel anticancer agent in vitro in the Year 2000 (Published in Ko et al. Can Lett 173:83–91, 2001), and also as a highly effective and rapid anticancer agent in vivo shortly thereafter (Ko et al. Biochem Biophys Res Commun 324:269–275, 2004), its efficacy as a potent anticancer agent in humans was demonstrated. Here, based on translational research, we report results of a case study in a young adult cancer patient with fibrolamellar hepatocellular carcinoma. Thus, a bench side discovery in the Department of Biological Chemistry at Johns Hopkins University, School of Medicine was taken effectively to bedside treatment at Johann Wolfgang Goethe University Frankfurt/Main Hospital, Germany. The results obtained hold promise for 3BP as a future cancer therapeutic without apparent cyto-toxicity when formulated properly.

Keywords

3-bromopyruvate Cancer Liver cancer Fibrolamellar carcinoma Mitochondria Warburg Effect Hexokinase 2 Positron Emission Tomography (PET) 

References

  1. Abeysinghe SI, Baker PJ, Rice DW, Rodgers HF, Stillman TJ, Ko YH, McFadden BA, Nimmo BG (1991) J Mol Biol 220:13–16CrossRefGoogle Scholar
  2. Bustamante E, Pedersen PL (1977) Proc Natl Acad Sci 74:3735–3739CrossRefGoogle Scholar
  3. Guterman L (2011) Chem Eng News 89:15–19Google Scholar
  4. Ido T, Wan CN, Casella V, Fowler JS, Wolf AP, Reivich M, Kuhl DE (1978) J Lab Comp Radiopharma 14:175–182CrossRefGoogle Scholar
  5. Jarvis LM (2011) Chem Eng News 89:15–19Google Scholar
  6. Ko YH, McFadden BA (1990) Arch Biochem Biophys 278:373–380CrossRefGoogle Scholar
  7. Ko YH, Pedersen PL, Geschwind JF (2001) Cancer Lett 173:83–91CrossRefGoogle Scholar
  8. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, Pedersen PL (2004) Biochem Biophys Res Commun 324:269–275CrossRefGoogle Scholar
  9. Mathupala SP, Ko YH, Pedersen PL (2009) Semin Cancer Biol 19:17–24CrossRefGoogle Scholar
  10. Mathupala SP, Ko YH, Pedersen PL (2010) Biochim Biophys Acta 1797:1225–1230CrossRefGoogle Scholar
  11. Meloche HP, Monti CT (1967) Biochemistry 6:2273–2280CrossRefGoogle Scholar
  12. Pedersen PL (1978) Prog Exp Tumor Res 22:190–274Google Scholar
  13. Pedersen PL (2007a) J Bioenerg Biomemb 39:1–12CrossRefGoogle Scholar
  14. Pedersen PL (2007b) J Bioenerg Biomemb 39:211–222CrossRefGoogle Scholar
  15. Staub M, Denes G (1967) Biochim Biophys Acta 132:519–521Google Scholar
  16. Warburg O (1956) Science 124:269–270Google Scholar

Copyright information

© The Author(s) 2012

Authors and Affiliations

  • Y. H. Ko
    • 2
  • H. A. Verhoeven
    • 3
  • M. J. Lee
    • 4
  • D. J. Corbin
    • 5
  • T. J. Vogl
    • 6
  • P. L. Pedersen
    • 1
    • 7
    • 8
  1. 1.Department of Biological ChemistryJohns Hopkins University, School of MedicineBaltimoreUSA
  2. 2.Cancer Cure Med LLCOwings MillsUSA
  3. 3.Bioscience, Plant Research InternationalWageningen University and Research CentreWageningenThe Netherlands
  4. 4.Department of Internal MedicineSeoul National University HospitalSeoulSouth Korea
  5. 5.Oncology FoundationNew YorkUSA
  6. 6.Institut für Diagnostische und Interventionelle RadiologieJohann Wolfgang Goethe-Universität Frankfurt / MainFrankfurt am MainGermany
  7. 7.Department of Oncology and Sidney Kimmel Cancer CenterJohns Hopkins University, School of MedicineBaltimoreUSA
  8. 8.Center for Metabolism and Obesity ResearchJohns Hopkins University, School of MedicineBaltimoreUSA

Personalised recommendations